Back to List View Graph View

Tyrosine-kinase inhibitor

Tyrosine-kinase inhibitors (TKIs) are a class of targeted therapies designed to block the activity of tyrosine kinases, enzymes that transmit growth, survival, and differentiation signals through phosphorylation-dependent signaling pathways.

Where the papers sit

17 papers from the last 6 months study tyrosine-kinase inhibitor directly · updated from PubMed 13 Nov 2026

  • Long-Term CML TKI Management

    Chronic myeloid leukemia care is moving beyond response toward durable treatment-free remission and safer long-term TKI use. Molecular relapse surveillance and adherence remain central after imatinib, nilotinib, or dasatinib. Patient-reported monitoring and studies of arterial stiffness address quality of life and vascular risk. Third-generation agents such as vamotinib and TKI maintenance after brexucabtagene autoleucel extend the question to resistant Philadelphia chromosome-positive disease.

    6 papers · 35.3%

  • Immunotherapy–TKI Cancer Combinations

    Hepatocellular carcinoma work is converging on combinations of TKIs with PD-1 blockade, TACE, radiotherapy, or metabolic therapy. Camrelizumab–apatinib regimens and lenvatinib plus ADI-PEG 20 are being judged by response, progression-free survival, and safety, but much evidence remains early or retrospective. FAP-α-responsive nanoparticles aim to remodel fibrotic stroma and improve drug penetration. The same combination logic appears in PIK3CA-mutant cervical cancer and VEGF-treated renal or thyroid cancer, leaving comparative benefit and toxicity unresolved.

    6 papers · 35.3%

  • Resistance in Solid Tumors

    EGFR-TKI resistance is being addressed through molecular detection and pharmacologic optimization. NF-κB/ALDH1A1 provides a non-mutational mechanism in non-small cell lung cancer, while biosensors seek resistance mutations. Brain-penetrant inhibitors are being linked to intracranial exposure and response, and HER2 strategies are moving beyond amplification. Mefatinib versus gefitinib adds comparative first-line evidence in EGFR-mutated disease.

    5 papers · 29.4%

NEW DIRECTION

TKI therapy becomes a finite intervention that can be followed by treatment-free remission

The EURO-SKI biomarker study in chronic myeloid leukemia examined patients after tyrosine-kinase-inhibitor discontinuation and distinguished sustained treatment-free remission from molecular relapse using transcriptomic and immune-cell communication patterns. Rather than treating TKI therapy as necessarily ongoing, it presents treatment cessation—and the biological monitoring of remission afterward—as a therapeutic-management role for the inhibitor 42315627Jun.

NEW DIRECTION

Sorafenib can function as a stromal-targeted nanotherapeutic payload in fibrotic hepatocellular carcinoma

The FAP-α-responsive size-transformable lipid nanoparticle study in fibrotic hepatocellular carcinoma incorporated sorafenib with doxorubicin into a carrier that targets activated hepatic stellate cells, responds to tumor fibroblast-associated protease activity, remodels the stromal compartment, and improves drug penetration. This recasts the TKI as one component of an adaptive, stroma-directed delivery system rather than solely as a conventionally administered kinase-blocking drug 42328782Jun.

Papers

The 17 papers from the last 6 months that study tyrosine-kinase inhibitor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Long-Term CML TKI Management (6)
  1. Development, validation, and pilot-testing of a comprehensive patient-reported EORTC custom questionnaire for monitoring real-world tyrosine kinase toxicity in chronic myeloid leukemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 12 Nov 2026 PMID 43018785
  2. Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor? Journal of hematology & oncology · 27 Oct 2026 PMID 42934771
  3. Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol. PloS one · 18 Sept 2026 PMID 42758748
  4. Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
  5. Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood advances · 25 Jun 2026 PMID 42349018
  6. Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. Leukemia · 18 Jun 2026 PMID 42315627
Immunotherapy–TKI Cancer Combinations (6)
  1. Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma. Medicine · 17 Oct 2026 PMID 42888556
  2. Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PloS one · 29 Sept 2026 PMID 42809552
  3. The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379775
  4. Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
  5. FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
  6. Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension (Dallas, Tex. : 1979) · 20 May 2026 PMID 42158981
Resistance in Solid Tumors (5)
  1. A Systematic Intracranial Exposure-Response Evaluation of Brain-Penetrant Inhibitors: Informing Dose Selection for Brain Metastases. Clinical and translational science · 16 Oct 2026 PMID 42886004
  2. Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Signal transduction and targeted therapy · 12 Aug 2026 PMID 42586967
  3. Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer. Oncogene · 23 Jul 2026 PMID 42493544
  4. Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
  5. A tri-modal biosensor based on alkyne-functionalized gold nanoparticles and molecular beacon for detection of resistance-related point mutations in epidermal growth factor receptor-tyrosine kinase inhibitors. Molecular biology reports · 22 May 2026 PMID 42171913

By study type

Clinical trials (3)
  1. Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Signal transduction and targeted therapy · 12 Aug 2026 PMID 42586967
  2. Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377073
  3. Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension (Dallas, Tex. : 1979) · 20 May 2026 PMID 42158981
Observational studies and case reports (5)
  1. Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma. Medicine · 17 Oct 2026 PMID 42888556
  2. Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PloS one · 29 Sept 2026 PMID 42809552
  3. Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
  4. The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379775
  5. Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. Leukemia · 18 Jun 2026 PMID 42315627
Human data, design not indexed (6)
  1. Development, validation, and pilot-testing of a comprehensive patient-reported EORTC custom questionnaire for monitoring real-world tyrosine kinase toxicity in chronic myeloid leukemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 12 Nov 2026 PMID 43018785
  2. A Systematic Intracranial Exposure-Response Evaluation of Brain-Penetrant Inhibitors: Informing Dose Selection for Brain Metastases. Clinical and translational science · 16 Oct 2026 PMID 42886004
  3. Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol. PloS one · 18 Sept 2026 PMID 42758748
  4. Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
  5. Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood advances · 25 Jun 2026 PMID 42349018
  6. A tri-modal biosensor based on alkyne-functionalized gold nanoparticles and molecular beacon for detection of resistance-related point mutations in epidermal growth factor receptor-tyrosine kinase inhibitors. Molecular biology reports · 22 May 2026 PMID 42171913
Preclinical: animal, cell and lab studies (3)
  1. Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor? Journal of hematology & oncology · 27 Oct 2026 PMID 42934771
  2. Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer. Oncogene · 23 Jul 2026 PMID 42493544
  3. FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782